⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MCRB News
Seres Therapeutics, Inc.
Form 8-K
sec.gov
MCRB
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
globenewswire.com
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MCRB
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
MCRB
Form 8-K
sec.gov
MCRB
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
globenewswire.com
MCRB
Form 8-K
sec.gov
MCRB
Form 8-K
sec.gov
MCRB
Form 8-K
sec.gov
MCRB
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
globenewswire.com
MCRB